Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?

Future Oncol. 2022 Feb;18(5):519-522. doi: 10.2217/fon-2021-1309. Epub 2022 Jan 24.
No abstract available

Keywords: immunotherapy; ipilimumab; nivolumab; pembrolizumab; renal cell carcinoma; tyrosine kinase inhibitor.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunotherapy / methods
  • Kidney Neoplasms / drug therapy*
  • Nephrectomy

Substances

  • Antibodies, Monoclonal, Humanized
  • Immune Checkpoint Inhibitors
  • pembrolizumab